Title: Tolfenamic Acid and Leukotriene Synthesis Inhibition
Abstract: Pharmacology & ToxicologyVolume 75, Issue s2 p. 60-63 Tolfenamic Acid and Leukotriene Synthesis Inhibition Eeva Moilanen, Eeva Moilanen Department of Clinical Pharmacology, Tampere University Hospital, Tampere, FinlandSearch for more papers by this authorHannu Kankaanranta, Hannu Kankaanranta Department of Clinical Pharmacology, Tampere University Hospital, Tampere, FinlandSearch for more papers by this author Eeva Moilanen, Eeva Moilanen Department of Clinical Pharmacology, Tampere University Hospital, Tampere, FinlandSearch for more papers by this authorHannu Kankaanranta, Hannu Kankaanranta Department of Clinical Pharmacology, Tampere University Hospital, Tampere, FinlandSearch for more papers by this author First published: October 1994 https://doi.org/10.1111/j.1600-0773.1994.tb02000.xCitations: 24AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References Abramson, S. B. & G. Weissmann: The mechanisms of action of non-steroidal anti-inflammatory drugs. Arthritis Rheum. 1989, 32, 1– 9. Ackerman, N. R., E. C. Arner, W. Galbraith, R. R. Harris, B. D. Jaffee & W. M. Mackin: Anti-inflammatory consequences of 5-lipoxygenase inhibition. Adv. Prostaglandin Thromboxane Leukotriene Res. 1986, 16, 47– 62. Altman, R. D.: Neutrophil activation: an alternative to prostaglandin inhibition as the mechanism of action for NSAIDs. Semin. Arthritis Rheum. 1990, 19 (suppl 2), 1– 5. Axelsson, C. K., L. V. Christiansen, A. Johansen & P. E. Poulsen: Comparative effects of tolfenamic acid and acetylsalicylic acid on human gastric mucosa. Scand J. Rheumatol. 1977, 6, 23– 27. Ballinger, A. B., P. J. Kumar & D. L. Scott: Misoprostol in the prevention of gastroduodenal damage in rheumatology. Ann. Rheum. Dis. 1992, 51, 1089– 1093. Bhattacherjee, P., N. K. Boughton-Smath, R. L. Follenfant, L. G. Garland, G. A. Higgs, H. F. Hodson, P. J. Islip, W. P. Jackson, S. Moncada, A. N. Payne, R. W. Randall, C. H. Reynolds, J. A. Salmon, J. E. Tateson & B. J. R. Whittle: The effects of a novel series of selective inhibitors of arachidonate 5-lipoxygenase on anaphylactic and inflammatory responses. Ann. New York Acad, Sci. 1988, 524, 307– 320. Black, A. K., R. D. R. Camp, A. I. Mallet, F. M. Cunningham, M. Hofbrauer & M. W. Greaves: Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J. Invest. Dermatol. 1990, 95, 50– 54. Blackburn, Jr., W. D., L. W. Heck, L. D. Loose, J. D. Eskra & T. J. Carty: Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis Rheum. 1991, 34, 204– 210. Christie, P. E., P. Tagari, A. W. Ford-Hutchinson, S. Charlesson, P. Chee, J. P. Arm & T. H. Lee: Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive astmatic subjects. Am. Rev. Resp. Dis. 1991, 143, 1025– 1029. Collawn, C., P. Rubin, N. Perez, J. Bobadilla, G. Cabrera, E. Reyes, J. Borovoy & D. Kershenobich: Phase II study of the saety and efficacy of a 5-lipoxygenase inhibitor in patients with ulcerative colitis. Am. J. Gastroenterol. 1992, 87, 342– 346. Gögelein, H., D. Dahlem, H. C. Englert & H. J. Lang: Flufenamic acid, mefenamic acid and niflumic acid inhibit single nonselective cation channels in the rat exocrine pancrease. FEBS Lett. 1990, 268, 79– 82. Higgs, G. A., R. L. Follenfant & L. G. Garland: Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamine acids; effects on acute inflammatory response. Br. J. Pharmacol. 1988, 94, 547– 551. Higgs, G. A. & J. R. Vane: Inhibition of cyclo-oxygenase and lipoxygenase. Br. Med. Bull. 1983, 39, 265– 270. Kankaanranta, H., E. Moilanen & H. Vapaatalo: Tolfenamic acid inhibits leukotriene B4-induced chemotaxis of polymorphonuclear leukocytes in vitro. Inflammation 1991, 15, 137– 143. Kankaanranta, H., E. Moilanen & H. Vapaatalo: Comparison of the in vitro effects of flunixin and tolfenamic acid on human leukocyte and platelet functions. Inflammation 1993, 17, 417– 425. Kivinen, A., E. Moilanen & H. Vapaatalo: Tolfenamic acid prevents ethanol- or acetylsalicylic acid-induced gastric ulcers in the rat. Scand. J. Rheumatol. 1990, Suppl 85, 59. Knapp, H. R., K. Sladek & G. A. Fitzgerald: Increased excretion of leukotriene E4 during aspirin-induced asthma. J. Lab. Clin. Med. 1992, 119, 48– 51. Lam, S., H. Chan, J. C. LeRiche, M. Chan-Yeung & H. Salari: Release of leukotrienes in patients with bronchial asthma. J. Allergy Clin. Immunol. 1988, 81, 711– 717. Moilanen, E., J. Alanko, E. Seppälä & H. Vapaatalo: Effects of antirheumatic drugs on leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Agents Actions 1988, 24, 387– 394. Moilanen, E., J. Alanko, A. Juhakoski & H. Vapaatalo: Orally administered tolfenamic acid inhibits leukotriene synthesis in isolated human peripheral polymorphonuclear leukocytes. Agents Actions 1989, 28, 83– 88. Musser, J. H. & A. F. Kreft: 5-Lipoxygenase: properties, pharmacology and the quinolinyl(-bridged) aryl class of inhibitors. J. Med. Chem. 1992, 35, 2501– 2524. Palmer, R. M. J. & J. A. Salmon: Inhibition of 5-lipoxygenase: relevance to inflammation. In: Eds.: B. Samuelsson, F. Berti, G. C. Folco & G. P. Velo. Drugs affecting leukotrienes and other eicosanoid pathways. Plenum Press, New york, 1985, pp. 311– 330. Picado, C., I. Ramis, P. J. Rosello, O. Bulbena, V. Plaza, J. M. Montserrat & E. Gelpi: Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirinsensitive asthmatic patients. Am. Rev. Respir. Dis. 1992, 145, 65– 69. Pichurko, B. M., J. R. H. Ingram, R. I. Sperling, J. E. Lafleur, E. J. Corey, K. F. Austen & J. M. Drazen: Localization of the site of the bronchoconstrictor effects of leukotriene C4 compared with that of histamine in asthmatic subjects. Am. Rev. Respir. Dis. 1989, 140, 334– 339. Rola-Pleszczynski, M. & J. Stankova: Cytokine gene regulation by PGE2, LTB4 and PAF. Med. Inflammation 1992, 1, 5– 8. Shindo, K., Y. Matsumoto, M. Matsumura, M. Sumimoto & T. Okubo: Leukotriene E4 in arterial blood of astmatic patients during remission. Curr. Ther. Res. 1991, 50, 1– 9. Sperling, R. I., A. I. Benincaso, R. J. Anderson, J. S. Coblyn, K. F. Austen & M. E. Weinblatt: Acute and chronic suppression of leukotriene B4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum. 1992, 35, 376– 384. Wallace, J. L. & D. N. Granger: Pathogenesis of NSAID gastropathy: are neutrophils the culprits Trends Pharmacol. Sci. 1992, 13, 129– 131. Weinblatt, M., J. Kremer, S. Helfgott, J. Coblyn, A. Maier, R. Sperling, G. Petrillo, J. Kesterson, L. Dube, B. Henson, N. Teoh & P. Rubin: A 5-lipoxygenase inhibitor in rheumatoid arthritis (RA). Arthritis Rheum. 1990, 33, S152. Citing Literature Volume75, Issues2October 1994Pages 60-63 ReferencesRelatedInformation
Publication Year: 1994
Publication Date: 1994-10-01
Language: en
Type: review
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 30
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot